Hume Brophy

Lobbying Organisation Hume Brophy

Date published 21 Sep, 2022

Relevant Matter Public policy or programme

Public Policy Area Health

Period 1 May, 2022 to 31 Aug, 2022

Specific Details European Pharmaceutical Strategy

Intended results Discussion on implementation of the European Pharmaceutical Strategy and matters related to Diversity and Inclusion

Name of person primarily responsible for lobbying on this activity Catherine Owen

Did any Designated Public Official(DPO) or former Designated Public Official(DPO) carry out lobbying activities on your behalf in relation to this return? You must include yourself, and answer Yes, if you are a current DPO or a DPO at any time in the past. (What is a Designated Public Official?) No

Did you manage or direct a grassroots campaign? No

Was this lobbying done on behalf of a client? Yes

Client(s)

Client 1

Company name Bristol Myers Squibb

CRO number (if applicable)

Company address Rue de Trône 108 3rd Floor 1050 Brussels, Belgium

Main business or activity Health

Company website

Contact email address Douglas.Gregory@bms.com

Contact phone number + 32 496 26 40 77

Contact address

Lobbying activity

The following activities occurred for this specific Subject Matter Area.

Meeting (1)

Meeting with MEP Frances Fitzgerald to discuss the European Pharmaceutical Strategy and matters related to Diversity & Inclusion.

Designated public officials lobbied

The following DPOs were lobbied during this return period on this specific Subject Matter Area. These DPOs were involved in at least one of the Lobbying Activities listed above, but not necessarily all of them. As returns are specific to a Subject Matter Area the above Lobbying Activities may be associated with multiple returns.

Frances Fitzgerald MEP (European Parliament)